Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside compound as a potential treatment for Parkinson’s disease.

Under the agreement, Niagen Bioscience obtains exclusive rights to key intellectual property, know-how, and clinical data expected to bolster future regulatory submissions for Parkinson’s therapy approval within the European Union. The license is based on findings from the NOPARK trial, a phase III clinical study involving 400 patients with early-stage Parkinson’s across 12 Norwegian sites.

The NOPARK trial, completed in June 2025, was a randomized, double-blind, placebo-controlled study where participants received either 500 mg of nicotinamide riboside twice daily or a placebo over 52 weeks. Final results are anticipated by the end of 2025.

“This milestone underscores our long-term commitment to translating scientific innovation into meaningful therapeutic solutions,” said Rob Fried, CEO of Niagen Bioscience.

This collaboration builds on a research partnership that began in March 2018 between Dr. Charalampos Tzoulis of Haukeland University Hospital and Niagen Bioscience’s external research program, supporting four clinical trials exploring nicotinamide riboside’s effects on Parkinson’s disease.

To facilitate its shift from supplement development to regulated drug research for neurodegenerative disorders, Niagen Bioscience has created a wholly owned subsidiary aligned with the new licensing agreement.

Niagen Bioscience stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.